Clene Approves Stock Plan Amendment at Annual Meeting

Clene ( (CLNN) ) just unveiled an update.

On May 22, 2025, Clene Inc. held its Annual Meeting of Stockholders, where the stockholders approved an amendment to the company’s 2020 Stock Plan, increasing the number of shares of common stock reserved for issuance by 800,000 shares. Additionally, the Board of Directors approved an amendment to the compensation program for nonemployee directors, adjusting stock option grants to reflect a reverse stock split from July 2024. These changes are expected to impact the company’s stock management and director compensation structure, potentially affecting shareholder value and governance practices.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Underperform.

Clene’s stock score reflects significant financial distress characterized by declining revenues, persistent net losses, and negative equity. The bearish technical indicators and negative valuation metrics further weaken investor confidence. While corporate announcements about advancements in neurological treatments provide a slight positive outlook, they are insufficient to offset the company’s broader financial challenges and delisting risks.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Average Trading Volume: 59,290

Technical Sentiment Signal: Sell

Current Market Cap: $22.01M

See more insights into CLNN stock on TipRanks’ Stock Analysis page.